Article Text

Download PDFPDF
Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis
  1. A W R van Kuijk1,2,
  2. M de Groot3,
  3. S O Stapel4,
  4. B A C Dijkmans2,5,
  5. G J Wolbink2,4,
  6. P P Tak1
  1. 1 Division of Clinical Immunology and Rheumatology, Academic Medical Centre/University of Amsterdam, Amsterdam, The Netherlands
  2. 2 Jan van Breemen Institute, Amsterdam, The Netherlands
  3. 3 Department of Dermatology, Academic Medical Centre/University of Amsterdam, Amsterdam, The Netherlands
  4. 4 Sanquin Research, Amsterdam, The Netherlands
  5. 5 Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
  1. Correspondence to Professor P P Tak, Division of Clinical Immunology and Rheumatology, F4-105, Academic Medical Centre/University of Amsterdam, Meibergdreef 9, NL-1105 AZ Amsterdam, The Netherlands; p.p.tak{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

While the majority of patients with psoriatic arthritis (PsA) respond well to treatment with adalimumab, some patients lose response.1 An explanation might be the development of antiadalimumab antibodies, which has been reported in rheumatoid arthritis.2 3 Therefore, we studied the incidence of antiadalimumab antibodies in PsA, and the relationship with serum adalimumab concentration and clinical response.

Twenty-two patients with active PsA, fulfilling CASPAR classification criteria,4 started adalimumab treatment (table 1). The patients met the requirements of the Dutch consensus on initiation of tumour necrosis factor blocking therapy in PsA5 and were seen at baseline, and after 3 and 12 months. Serum samples were collected just before the next injection with adalimumab. The Disease Activity Score in 28 joints (DAS28), which has been shown to discriminate between active drug and placebo in clinical trials in …

View Full Text


  • Competing interests BACD is a member of the advisory board of Abbott and has received honoraria for lectures. PPT has served as a consultant to Abbott, Schering-Plough, UCB and Wyeth.

  • Ethics approval Ethics committee approval from Academic Medical Centre/University of Amsterdam.

  • Patient consent Patient consent received.

  • Provenance and peer review Not commissioned; externally peer reviewed.